GSK Products | GSKPro for Healthcare Professionals
Explore the list of the GSK products available for use, view prescribing information, and access detailed Healthcare Professional websites.
Products A-Z - GSK
Products A-Z. Below you can find a full list of our products. Our vaccines and medicines are approved in individual countries for specific uses and the information we provide is governed by local regulation. Patients should always ask a healthcare professional for advice.
GSK confirms closure of agreement to divest anaesthesia portfolio …
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the closure of an agreement with Aspen (JSE: APN) aligned with GSK’s strategy of simplification through focusing on core therapeutic areas. GSK has divested its anaesthesia portfolio to Aspen (excluding the US and Canada which had been previously divested) for £180m plus milestones of up to ...
Products - GSK
General medicines include our inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases, in a portfolio which includes pre-launch R&D assets, growth and established products. Every day, our general medicines improve health and make life better for millions all over the world and our portfolio of more than 150 primary ...
Products | Oncology | GSK US Medical Affairs
Find GSK US oncology product information: Prescribing Information, storage and handling, and more.
GSK continues sell-off of non-core assets - BioPharma Dive
2016年9月12日 · The British pharma is selling its anesthesia business to Aspen Therapeutics for £180 million ($240 million) upfront plus £100 million ($133 million). In addition, the companies have ended their commercialization agreement in sub-Saharan Africa, but will continue to market their own products in the region.
Remimazolam: Non-Clinical and Clinical Profile of a New Sedative ...
2021年7月20日 · For induction of anesthesia, a short infusion of 6 or 12 mg/kg/h was used, and for maintenance of anesthesia, a dose of 1–2 mg/kg/h. The primary endpoints were successful anesthesia as defined by the lack of intra-operative awakening or recall, no requirement for rescue sedation, and no body movement.
Products | GSK Canada
Our product areas. Our portfolio spans three product areas: vaccines, specialty and general medicines. We’re prioritizing R&D investment in vaccines and specialty medicines, which we expect to grow to around three quarters of our business by 2026. Vaccines. Our unrivalled vaccine portfolio targets infectious diseases at every stage of life.
Products | GSK AU
Our product areas. Our portfolio spans three product areas: vaccines, specialty and general medicines. We’re prioritising R&D investment in vaccines and specialty medicines, which we expect to grow to around three quarters of our business by 2026.
Products | GSK US
Products. Learn more about our product portfolio and how we're prioritizing vaccines and specialty medicines to get ahead of disease together. Below you can find the full A-Z list of our products available in the United States.